Compare Enbridge Inc (ENB) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enbridge Inc vs Illumina, Inc. — how do they compare? Enbridge Inc trades at $46.53 (market cap $103.38B), while Illumina, Inc. trades at $265.01 (market cap $39.95B). The key difference: Enbridge Inc is far larger — about 2.6× Illumina, Inc.'s market cap, and Enbridge Inc pays a 6.02% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enbridge Inc for 91 Days and Illumina, Inc. for 83 Days on average.
| ENB | ILMN | |
|---|---|---|
Market Cap | $103.38B | $39.95B |
Volume | 3,684,305 | 3,169,503 |
Sector | Energy | Health |
52-Week High | $58.04 | $293.69 |
52-Week Low | $45.23 | $91.00 |
Typical Hold Time | 91 Days | 83 Days |
Enterprise Value | $185.39B | $41.31B |
Dividend Yield | 6.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENB trades at $45.89, down 1.4% on the day, with a bearish technical signal but strong recent earnings beats. The company posted $65.19B in 2025 revenue, with net income of $7.49B and a 7.34% margin. Analysts maintain a consensus buy rating with a $61.63 price target, highlighting a 6% dividend yield and robust cash flow from operations of $12.27B.
Outlook is positive due to consistent EBITDA growth, a $41B project backlog, and defensive midstream assets, though risks include high debt levels and sensitivity to interest rates. The stock offers value with a P/E of 25.54 and P/S of 1.73, supported by institutional interest and dividend stability.
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
